Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Dina Erzina, Alice Capecchi, Sacha Javor, Jean-Louis Reymond
Summary: Researchers synthesized a library of peptide dendrimers with an amino acid composition similar to GA, some of which were as active as GA. Detailed profiling showed that the best hit dendrimer can induce the differentiation of monocytes towards an M2 state with a distinct immune marker profile. This peptide dendrimer might serve as a starting point to develop a well-defined immunomodulatory analog of GA.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Review
Clinical Neurology
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, Jeffrey A. Cohen, Christoph Kleinschnitz, Christian Wolf
Summary: Earlier diagnosis, access to disease-modifying therapies, and improved supportive care have positively influenced the disease course of multiple sclerosis, leading to improved long-term outcomes for patients. However, the complexity of treatment selection has increased due to the presence of comorbidities, immune senescence, and the growing number of approved therapies.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Mahmoud A. AbdelRazek, Subhash Tummala, Fariha Khalid, Shahamat Tauhid, Youmna Jalkh, Samar Khalil, Shelley Hurwitz, Jonathan Zurawski, Rohit Bakshi
Summary: This study compared gray matter atrophy in patients with multiple sclerosis (MS) treated with glatiramer acetate (GA) and patients with clinically benign MS (BMS). The results showed that there was no significant change in gray matter and whole brain atrophy in the GA group over 2 years, similar to the BMS group.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Ignacio Casanova, Maria I. Dominguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Angel Garcia-Martinez, Patricia Gomez, Sara Abellan, Esther De Antonio, Roberto Alvarez-Lafuente
Summary: This study investigates the association between a preselected list of miRNAs in the serum of relapsing-remitting multiple sclerosis (RRMS) patients with therapeutic response to Glatiramer Acetate (GA) and clinical evolution. The findings suggest that certain miRNAs may serve as potential biomarkers for disease progression and response to treatment in multiple sclerosis.
Article
Pharmacology & Pharmacy
Niloufar Rahiman, Parvin Zamani, Leila Arabi, Seyedeh Hoda Alavizadeh, Aminreza Nikpoor, Mohammad Mashreghi, Ali Badiee, Mahmoud Reza Jaafari
Summary: The study explores the use of liposomal formulations of Glatiramer acetate (GA) to overcome the frequent administration rate required for MS therapy. The results show that liposomal GA has higher efficacy in a murine model of MS, suggesting its potential as a reliable nanomedicine-based platform for MS treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Immunology
Candace Marsters, Nabeela Nathoo, Lindsay Amatto, Russell Wong, Muhammad N. Mahmood, Jennifer A. McCombe
Summary: Glatiramer acetate, an old and safe therapy for relapsing-remitting multiple sclerosis, can rarely cause urticarial vasculitis. We present a case of normocomplementemic urticarial vasculitis diagnosed by skin punch biopsy in a patient treated with glatiramer acetate for five years. The urticaria resolved after treatment with steroids and an antihistamine, as well as discontinuing glatiramer acetate.
JOURNAL OF NEUROIMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Berke Karaahmet, John A. Olschowka, M. Kerry O'Banion
Summary: Alzheimer's disease (AD) is a neurodegenerative disorder with strong inflammatory components. However, using glatiramer acetate (GA) to reduce amyloid beta (Aβ) plaque pathology in a mouse model of AD showed only modest decreases in Aβ levels during the development of pathology and unexpectedly increased Aβ levels in later stages. The impact was significant only in female mice and there were no changes in microglial uptake or immune markers on microglia. Caution is needed when repurposing GA for AD treatment.
Article
Biochemistry & Molecular Biology
Rina Aharoni, Raya Eilam, Shaul Lerner, Efrat Shavit-Stein, Amir Dori, Joab Chapman, Ruth Arnon
Summary: The study suggests that in MOG 35-55 induced EAE, neuronal loss is not due to apoptotic cell death but rather axonal damage present in the early stages of the disease. Elevated interstitial glutamate concentrations in the cerebrospinal fluid indicate the involvement of glutamate excess in the damage processes inflicted by this disease. Treatment with GA significantly reduces pathological manifestations such as apoptotic cell death, NFL leakage, histological tissue damage, and glutamate excess, demonstrating the neuroprotective effects of this therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Ioana S. Barac, Vitalie Vacaras, Mihaela Iancu, Dafin F. Muresanu, Lucia M. Procopciuc
Summary: This study aimed to test the association between interferon and long-chain synthesis gene polymorphisms with multiple sclerosis (MS) patients. The results showed a significant correlation between serum levels of IL-27 and IL-23 with gene polymorphisms in RRMS patients.
Review
Health Care Sciences & Services
Maria Jose Zarzuelo-Romero, Cristina Perez-Ramirez, Yasmin Cura, Maria Isabel Carrasco-Campos, Luciana Maria Marangoni-Iglecias, Maria Carmen Ramirez-Tortosa, Alberto Jimenez-Morales
Summary: The response to glatiramer acetate (GA) therapy in MS patients may be influenced by genetic polymorphisms in genes such as CD86, CTSS, and FAS. Identifying these polymorphisms could serve as a predictive marker for the response to GA treatment in the future, but further validation studies are needed.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Peter Lipsky, Patrick T. Vallano, Jeffrey Smith, Walter Owens, Daniel Snider, Viswanath Bandaru, Yunfu Sun, Ross Wallingford, Joseph Duncan, Joshua Lewis, Jason Southall, Azeem Ansari, Hong Li
Summary: The study demonstrates the equivalence of Mylan's glatiramer acetate (MGA) to the reference product Copaxone(R) (COP) in terms of physicochemical properties, structural signatures, and biological activity. The findings provide compelling evidence that the FDA-approved generic MGA can be substituted for COP in the treatment of patients with relapsing-remitting multiple sclerosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Ophthalmology
Joanna Roskal-Walek, Michal Biskup, Magdalena Dolecka-Slusarczyk, Anita Rosolowska, Andrzej Jaroszynski, Dominik Odrobina
Summary: Susac syndrome (SS) is difficult to diagnose as its clinical triad does not typically occur concurrently, often leading to misdiagnosis as other diseases like multiple sclerosis (MS). Combination therapy with corticosteroids, intravenous immunoglobulins, and azathioprine may improve SS symptoms.
Article
Clinical Neurology
Masoumeh Cheshmavar, Omid Mirmosayyeb, Negin Badihian, Shervin Badihian, Vahid Shaygannejad
Summary: The study found that both rituximab (RTX) and glatiramer acetate (GA) did not significantly affect the Expanded Disability Status Scale (EDSS) in secondary progressive multiple sclerosis (SPMS) patients, but were equally effective in reducing relapses.
ACTA NEUROLOGICA SCANDINAVICA
(2021)
